Eisai Co., Ltd. and Biogen Inc. have introduced the U.S. availability of LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating remedy in adults with early Alzheimer’s illness (AD). This new therapy possibility presents a substitute for intravenous (IV) dosing, enhancing comfort and adaptability for sufferers with delicate cognitive impairment or delicate dementia as a result of AD.
LEQEMBI IQLIK is run by way of an autoinjector, with an authorized initiation routine of 500 mg given weekly as two 250 mg injections. The therapy will also be used for upkeep dosing at 360 mg weekly following 18 months of IV or subcutaneous therapy. The flexibility to modify between IV and subcutaneous administration goals to cut back the time and assets related to conventional IV infusions.
The introduction of LEQEMBI IQLIK is anticipated to decrease limitations for sufferers beginning and persevering with therapy by permitting at-home administration, thus decreasing the necessity for clinic visits. This method not solely facilitates affected person mobility but additionally probably decreases healthcare assets concerned in IV dosing.
To assist the rollout, Eisai and Biogen are offering assets for sufferers, caregivers, healthcare suppliers, and pharmacies. These embrace tutorial movies, welcome kits, and the LEQEMBI Companion app, which presents training and monitoring instruments for sufferers. Support by way of the LEQEMBI Specialty Pharmacy Network contains help with prescription success, insurance coverage navigation, and academic assist throughout the preliminary months of remedy.
Financial help can also be obtainable by way of Eisai’s Patient Assistance Program, providing LEQEMBI without charge to eligible uninsured sufferers who meet particular standards. This initiative is a part of a broader effort to make sure accessibility to the therapy for these in want.
LEQEMBI is indicated for the therapy of Alzheimer’s illness, particularly for sufferers on the delicate cognitive impairment or delicate dementia stage, aligning with the inhabitants studied in scientific trials. Eisai leads the worldwide improvement and regulatory submissions for lecanemab, with each Eisai and Biogen co-commercializing and co-promoting the product.